Is TRVI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Haduvio Phase 3 in IPF-related chronic cough, with product revenue (ttm) at ~$0 (clinical stage, no approved products). The bear case rests on trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Analysts covering it are spread from $20.00 to $36.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $20.00, +11.5% from the $17.93 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Haduvio Phase 3 in IPF-related chronic cough. The lead program advanced into Phase 3 in early 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. The most optimistic analyst target on TRVI is $36.00, +100.8% from the $17.93 price. That figure is only reachable if this thesis works close to its best case.

Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Finally, the ~$2 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline. The most pessimistic published target is $20.00, +11.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Haduvio Phase 3 in IPF-related chronic cough) stalling in the reported numbers rather than in the narrative, the risk above (trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Trevi is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine extended release), an experimental therapy for chronic cough in idiopathic pulmonary fibrosis, other interstitial lung disease, and refractory chronic cough. It has no approved products yet.

No. Trevi has no approved products and generates no product revenue. Like most clinical-stage biotechs, it operates at a net loss and funds its research through cash raised in stock offerings, most recently about $162 million in net proceeds in April 2026.

Haduvio is Trevi's lead drug candidate, an oral extended-release formulation of nalbuphine. It works on the cough reflex as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists used by many competing chronic cough programs.